Biotech News - HTG Appoints William Radany CEO - HTG, Inc.

HTG Appoints William Radany CEO

HTG, Inc., a provider of novel array-based gene expression assay
technology and services for the life sciences industry, today
announced the appointment of Dr. William Radany to the position of
chief executive officer. He replaces Kirk Collamer who will remain
with the company as the chief financial officer. Dr. Radany joins
HTG from Chemicon International, one of the leading resources for
immunological reagents, immunodiagnostics, and molecular biology
products, where he was vice president of business segment
management.

"Bill Radany is a proven industry leader who brings more than 20
years of experience in the pharmaceutical and drug discovery
technologies industries to HTG," said Bruce Seligmann, chairman,
HTG. "His strong leadership and management skills will be
instrumental in guiding the company's pursuit of both short and long-
term growth objectives."

"I am excited to work closely with the Board of Directors and the
management team at HTG to continue to bring the Company's gene
expression profiling technology to the forefront of drug discovery
research. HTG's technology platform brings tremendous value to lab
researchers," said Dr. Radany. "With my experience at life sciences
and biotech companies alike, I'm looking forward to applying my
experience and insight at HTG to take the business to the next level
and expand the Company's customer base which currently includes
leading pharmaceutical companies such as Merck & Co., Sanofi
Aventis, Bristol Meyers Squibb, Celgene and Takeda, Inc."

Prior to Chemicon International, Dr. Radany was chief business
officer at Xencor where he headed up corporate strategy for
partnering of Xencor proteomics technologies. He has also served as
vice president of drug discovery programs at both Caliper
Technologies Corp. and Strategene respectively. Prior to Strategene,
Dr. Radany was president of Biacore, a proteomics technology company
and previously founded the in vitro diagnostic cell culture company
NeoGenex and subsequently sold the Company to Diagnostic Hybrids,
Inc.

Dr. Radany earned a B.S. in cell biology from Colorado State
University and a doctorate in biochemistry/physiology from the
University of Wyoming.

HTG's ArrayPlate qNPA(TM) technology is used to carry out
quantitative multiplexed, gene-based drug discovery programs,
including target validation, HTS lead optimization, metabolism,
toxicology and clinical development. HTG's ArrayPlate lysis-only
quantitative Nuclease Protection Assay (qNPA(TM)) platform allows
scientists to test any sample while avoiding the need for extraction
or target amplification. The platform provides robust, high-quality
quantitative test results, including QSAR-quality dose response data
and EC50's, enabling clients to compress drug discovery and
development program timelines, increase program success and reduce
costs.

About HTG

HTG provides ArrayPlate qNPA technology and services for the life
sciences industry, addressing current unmet needs and enabling a new
era of drug discovery and diagnostics. The company's ArrayPlate
technology platform enables the accurate, sensitive, reproducible
and repeatable measurement of molecular signatures through the
multiplexed measurement of RNA expression levels, DNA and protein
levels and function. ArrayPlate qNPA data measure how drugs act and
diseases are mediated at the level of whole cells, tissues, or
organisms. This enables researchers to focus their resources by
rapidly obtaining higher quality results than possible with other
methods, in days rather than months, saving time and cost while
addressing critical unmet needs. Privately-held HTG is based in
Tucson, Arizona. Investors in the company include Solstice Capital,
Valley Ventures, and Village Ventures. Additional information is
available at www.htgenomics.com.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/